Cochrane · systematic review · CD009027
Antiepileptic drugs for seizure control in people with neurocysticercosis
Walton, D, Castell, H, Collie, C, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
2
current version
GRADE rated
2
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 50%Low 1 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 3 versionsShort‐duration antiepileptic drug treatment compared with long‐duration antiepileptic drug treatment for people with neurocysticercosis
Population: people with neurocysticercosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Seizure control(seizure recurrence) Short‐duration antiepileptic drug treatment vs long‐duration antiepileptic drug treatment | OR 1.34 [0.73, 2.47] | 3 studies · 360 participants | Low Downgraded: risk of bias, indirectness |
Six‐ to 12‐month antiepileptic drug treatment compared with 24‐month antiepileptic drug treatment for seizure control in neurocysticercosis
Population: people with neurocysticercosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Seizure control (seizure recurrence) Six‐ to 12‐month antiepileptic drug treatment vs 24‐month antiepileptic drug treatment | OR 1.36 [0.72, 2.57] | 3 studies · 385 participants | Very low Downgraded: risk of bias, inconsistency, indirectness, publication bias |